- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Victoria Bae-Jump on Challenges in Treating Patients With Endometrial Cancer
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor, explained Victoria Bae-Jump, MD, PhD, associate professor, gynecologic oncology, University of North Carolina Lineberger Comprehensive Cancer Center.
Transcript
What challenges are you faced with in the treatment of patients with advanced and/or recurrent endometrial cancer?
I think the hardest thing about advanced and recurrent endometrial cancer is that the outcomes are still fairly poor for advanced endometrial cancers. You know, the overall 5-year survival is anywhere from 15% to 40%, depending on hat study you have, and we don’t have a very long list of agents, cytotoxics or targeted agents, that endometrial cancer responds to. Recurrent disease is even more dismal for endometrial cancer with actually survival after the diagnosis of recurrence being only between 14 and 15 months.
So, I think the hardest thing is that we don’t have many good treatments to offer advanced and recurrent endometrial cancer patients once we get passed paclitaxel and carboplatin. So, I think that’s the hardest thing to tell patients, that we don’t have as many options as we would like for them to be treated with.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
